Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized, double-blind trial of SHR-1139 Injection in moderate-to-severe plaque psoriasis
CTR20250864Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2025
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1139 in plaque psoriasis, psoriasis, sponsored by Hengrui Therapeutics. Started Apr 2025; status: active.
02
Drugs
SHR-1139
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on CTR20250864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250864.